News/ News/ News/ Oncology/ R&D EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout Phil Taylor ADC Therapeutics, antibody-drug conjugate, camidanlumab tesirine, Haematology, Oncology, Zynlonta 0 Comment ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase Share X EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout https://pharmaphorum.com/news/eha-adc-preps-filings-for-hodgkin-lymphoma-drug-after-ph2-readout/